Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

3448 Hemoglobin Decline and Health Outcomes in the Elderly:  the Cardiovascular Health Study

Monday, December 8, 2008, 5:30 PM-7:30 PM
Hall A (Moscone Center)
Poster Board III-530

Neil A Zakai, MD1, Benjamin French, PhD2*, Alice Arnold, PHD3*, Anne Newman, MD, MPH4*, Linda F. Fried, MD5*, John Robbins, MD6*, Paolo Chaves, MD, PHD7* and Mary Cushman, MD, MSc8

1Medicine, University of Vermont, Colchester, VT
2Biostatistics and Epidemiology, University of Pennsylvania, PA
3University of Washington, WA
4University of Pittsburgh, PA
5VA Pittsburgh Healthcare System, University of Pittsburgh, PA
6University of California, David, CA
7Johns Hopkins School of Public Health, MD
8University of Vermont, Colchester, VT

Introduction:  Anemia is associated with increased morbidity and mortality in the elderly, though the risk factors for and the consequences of hemoglobin (HGB) decline are poorly characterized.  Methods:  We studied 5201 men and women ≥65 participating in the Cardiovascular Health Study.  The cohort was followed biannually and had baseline and repeat hemograms 3 years later.  HGB decline was defined as 1) >1g/dL HGB drop, or 2) incident anemia at 3 years by WHO criteria.  Results:  4006 participants survived to 3 years and had two HGB measures.  The median HGB change was -0.2g/dL (IQR -0.8, 0.1).  961 (24%) participants had a >1g/dL HGB drop and 335 (8%) developed incident anemia.  The left side of the table presents adjusted logistic regression models of baseline risk factors for HGB decline.  Those with baseline cardiovascular disease (CVD), diabetes and kidney disease were more likely to develop >1g/dL HGB drop while only baseline kidney disease was associated with incident anemia.  The table also shows the adjusted risk of HGB decline with concurrent development of co-morbid conditions.  A >1g/dL drop in HGB was more likely in those who concurrently developed incident CVD, hypertension or inflammation.  Incident anemia was more likely in participants with concurrent development of kidney disease or inflammation. Both incident anemia and a HGB drop >1g/dL were associated with subsequent 9-year mortality adjusting for age, race, gender, year 3 HGB, hypertension, CVD, diabetes, and renal disease; HRs (95% CI) 1.4 (1.2, 1.6) and 1.2 (1.1, 1.4) respectively.  Discussion:  Among studied factors, baseline CVD, diabetes and kidney disease were risk factors for >1g/dL HGB drop while only baseline kidney disease was a risk factor for incident anemia.  Incident CVD and hypertension were associated concurrently with >1g/dL HGB drop while kidney disease was associated with concurrent incident anemia.  Inflammation development was the strongest risk factor accompanying HGB decline.  HGB decline, especially a 1g/dL drop, was associated with subsequent mortality irrespective of HGB concentration.  These data suggest that small HGB changes not captured by the WHO anemia criteria are associated with poor health outcomes and that inflammation is a major correlate of HGB decline in the elderly.  

Table:  Risk Factors for HGB Decline in Age-, Race-, Gender, and Baseline HGB-Adjusted Logistic Regression Models

Baseline Risk Factors for HGB Decline
Risk of HGB Decline with Concurrent Conditions

HGB Drop >1g/dL
Incident Anemia
HGB Drop >1g/dL
Incident Anemia
CVD
1.2
(1.1, 1.4)
1.0
(0.8, 1.3)
1.3
(1.1, 1.6)
1.0
(0.7, 1.3)
Hypertension
1.1
(0.99, 1.3)
1.1
(0.8, 1.2)
1.4
(1.1, 1.7)
1.1
(0.8, 1.5)
Diabetes
1.3
(1.1, 1.5)
1.1
(0.8, 1.4)
0.9
(0.6, 1.4)
0.8
(0.4, 1.7)
Kidney Disease
(GFR <60ml/min/1.73m2)
1.2
(1.0, 1.3)
1.3
(1.1, 1.7)
1.1
(0.8, 1.4)
1.5
(1.0, 2.1)
Inflammation
CRP ≥10mg/dL or
WBC≥15X109/mm3
1.0
(0.8, 1.3)
1.3
(0.99 1.8)
2.3
(1.8, 2.8)
2.3
(1.8, 3.0)

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH